Chemogenomic Strategies to Expand the Bioactive Chemical Space
Edgar Jacoby, Group Leader, Novartis, speaking at MedChem Europe
Date Posted: Saturday, March 12, 2011
Novartis Launches 'Novartis Access' Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month. Friday, September 25, 2015Novartis, Amgen Partner The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule. Friday, September 04, 2015EU Approves Novartis's laBCC Therapy Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy. Monday, August 24, 2015
Keeping Tumor Growth at Bay Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.Future of Medicine Could be Found in a Tiny Crystal Ball A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.Improving Delivery of Poorly Soluble Drugs Using Nanoparticles A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.Faster Drug Discovery? Startup develops more cost-effective test for assessing how cells respond to chemicals.New Mechanism of Antitumor Action Identified A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.Nanoparticles Deliver Tumor Suppressors to Damaged Livers UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.Experimental Combination Surprises with Anti-HIV Effectiveness A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.A New Type of Anticancer Agent Success in the development of a ?-tubulin specific inhibitor.Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs” In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.Versatile New Molecule-Building Technique Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.